Aerie Pharma shares battered as eye drug fails study

April 23, 2015 9:49 PM

15 0

(Reuters) - Aerie Pharmaceuticals Inc lost nearly three-quarters of its value after the company said its lead experimental eye drug failed a late-stage study.

The eye drop, Rhopressa, did not lower pressure inside the eye as much as timolol, a commonly prescribed drug, the company said.

Read more

To category page